Eosinophils in Health and Disease: A State-of-the-Art Review.


Journal

Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543

Informations de publication

Date de publication:
10 2021
Historique:
received: 13 01 2021
revised: 15 04 2021
accepted: 19 04 2021
pubmed: 21 9 2021
medline: 28 12 2021
entrez: 20 9 2021
Statut: ppublish

Résumé

Eosinophils play a homeostatic role in the body's immune responses. These cells are involved in combating some parasitic, bacterial, and viral infections and certain cancers and have pathologic roles in diseases including asthma, chronic rhinosinusitis with nasal polyps, eosinophilic gastrointestinal disorders, and hypereosinophilic syndromes. Treatment of eosinophilic diseases has traditionally been through nonspecific eosinophil attenuation by use of glucocorticoids. However, several novel biologic therapies targeting eosinophil maturation factors, such as interleukin (IL)-5 and the IL-5 receptor or IL-4/IL-13, have recently been approved for clinical use. Despite the success of biologic therapies, some patients with eosinophilic inflammatory disease may not achieve adequate symptom control, underlining the need to further investigate the contribution of patient characteristics, such as comorbidities and other processes, in driving ongoing disease activity. New research has shown that eosinophils are also involved in several homeostatic processes, including metabolism, tissue remodeling and development, neuronal regulation, epithelial and microbiome regulation, and immunoregulation, indicating that these cells may play a crucial role in metabolic regulation and organ function in healthy humans. Consequently, further investigation is needed into the homeostatic roles of eosinophils and eosinophil-mediated processes across different tissues and their varied microenvironments. Such work may provide important insights into the role of eosinophils not only under disease conditions but also in health. This narrative review synthesizes relevant publications retrieved from PubMed informed by author expertise to provide new insights into the diverse roles of eosinophils in health and disease, with particular emphasis on the implications for current and future development of eosinophil-targeted therapies.

Identifiants

pubmed: 34538424
pii: S0025-6196(21)00406-7
doi: 10.1016/j.mayocp.2021.04.025
pii:
doi:

Substances chimiques

Biological Factors 0
Eosinophil Granule Proteins 0
Receptors, Cell Surface 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2694-2707

Subventions

Organisme : NHLBI NIH HHS
ID : L30 HL124541
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Michael E Wechsler (ME)

Department of Medicine, National Jewish Health, Denver, CO. Electronic address: wechslerm@NJHealth.org.

Ariel Munitz (A)

Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Steven J Ackerman (SJ)

Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago.

Matthew G Drake (MG)

Division of Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland.

David J Jackson (DJ)

Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, United Kingdom; Asthma UK Centre, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.

Andrew J Wardlaw (AJ)

Institute for Lung Health, University of Leicester, Leicester, United Kingdom.

Stephanie K Dougan (SK)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA.

Sergejs Berdnikovs (S)

Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

Florence Schleich (F)

Department of Respiratory Medicine, CHU Liege, GIGA I(3), Research Group, University of Liege, Belgium.

Andrea Matucci (A)

Immunoallergology Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.

Pascal Chanez (P)

Department of Respiratory Diseases, C2VN INSERM INRAE Aix-Marseille University, Marseille, France.

Charlene M Prazma (CM)

Respiratory Therapeutic Area, GSK, Research Triangle Park, NC.

Peter Howarth (P)

Respiratory Medical Franchise, GSK, Brentford, United Kingdom.

Peter F Weller (PF)

Division of Allergy and Inflammation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Peter A Merkel (PA)

Division of Rheumatology, Department of Medicine, and Division of Clinical Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH